CDER seminar
This article was originally published in The Tan Sheet
Executive Summary
Long-term clinical research on traditional Chinese medicine (TCM) is needed to support efficacy of the herbs involved, according to Food & Drug Scientist Richard Ko, PhD, California Department of Health Services. Speaking during a CDER seminar Jan. 29, Ko stated "many of the clinical trials nowadays are too short," noting therapeutic benefits of TCM often "take months to years" to surface. In addition, herbal toxicity resulting from use of TCM, although it poses a "minimal" threat to public health, can be "pretty serious" when it does occur, Ko said. "We need to do a lot more to make sure that all the products that are sold out there are safe," he added, which includes "not only having GMPs, but also [good agricultural practices] as well as better education and better licensing for practitioners." Ko noted many herbs pose safety threats in the U.S. because they are not processed using traditional Chinese methods, which often leads to contamination...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.